The Potential Influence of Associated Antidepressants on the Pharmacokinetic Profile of Esketamine in Patients Affected by Treatment-resistant Depression.
Current Neuropharmacology April 7, 2025 Marika Alborghetti, Luana Lionetto, Ginevra Lombardozzi et al. 1 citation
Esketamine is administered intranasally in combination with at least another antidepressant in patients with treatment-resistant depression. Some of these antidepressants might affect ketamine's pharmacokinetic profile by inhibiting cytochrome-P450 (CYP450) isoforms. Our aim was to establish how different types of combined antidepressants affect serum and salivary levels of esketamine at the...
DOI: 10.2174/011570159X356952241216172603 (opens in new tab)
Full text (opens in new tab)
Depression
Antidepressant drugs
Cytochrome p450 isoenzymes.
Treatment-resistant
+3